New hope for hemophilia: safer switch to fitusiran?
NCT ID NCT06145373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether it is safe for males aged 12 and older with severe hemophilia A to switch from their current medicine (emicizumab) to a new one called fitusiran. About 20 participants will be followed for up to 28 months to check for side effects and how well the new medicine works. The goal is to find a better way to control bleeding episodes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Children's Hospital Los Angeles- Site Number : 8400005
RECRUITINGLos Angeles, California, 90027, United States
-
Investigational Site Number : 1580001
RECRUITINGTaipei, Podlaskie, 100, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- Newborn screening study aims to catch rare diseases at birth
- New clotting factor aims to stop bleeding in severe hemophilia a